Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)
December 11 2018 - 8:46AM
Edgar (US Regulatory)
Filed pursuant
to Rule 424(b)(3)
Registration No. 333-222967
PROSPECTUS SUPPLEMENT NO. 9
750,002 Common Shares
Auris Medical Holding AG
Common Shares
This Prospectus Supplement No. 9 (this “Prospectus
Supplement”) amends and supplements our Prospectus dated May 10, 2018 (the “Prospectus”), which forms a part
of our Registration Statement (our “Registration Statement”) on Form F-1 (Registration No. 333-222967). This Prospectus
Supplement is being filed to amend and supplement the information included or incorporated by reference in the Prospectus with
the information contained in this Prospectus Supplement. The Prospectus and this Prospectus Supplement relate to the resale of
up to 750,002 of our common shares issuable upon exercise of certain outstanding warrants.
This Prospectus Supplement includes information
from our Current Report on Form 6-K, which was filed with the Securities and Exchange Commission on December 11, 2018.
This Prospectus Supplement should be read
in conjunction with the Prospectus that was previously delivered, except to the extent that the information in this Prospectus
Supplement updates and supersedes the information contained in the Prospectus.
Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy
of this Prospectus Supplement or the Prospectus. Any representation to the contrary is a criminal offense.
The date of this Prospectus Supplement is
December 11, 2018.
On December 11, 2018, Auris Medical Holding AG (the “Company”
or “we”) entered into a purchase agreement (the “
Purchase Agreement
”) with FiveT Capital AG (“
FTC
”),
pursuant to which FTC committed to subscribe for 1,700,000 of our common shares for an aggregate price of $707,200, subject to
certain limitations and conditions set forth in the Purchase Agreement and pursuant to our effective shelf registration statement
on Form F-3 (Registration No. 333-228121), filed with the Securities and Exchange Commission (the “
SEC
”) in
accordance with the provisions of the Securities Act of 1933, as amended (the “
Securities Act
”), which was declared
effective on November 14, 2018 and the related prospectus supplement dated December 11, 2018.
The Purchase Agreement contains customary representations, warranties
and agreements of the parties, indemnification rights of FTC and other obligations of the parties.
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Apr 2023 to Apr 2024